Zevra Therapeutics’ Miplyffa approved for Niemann-Pick type C. Read why ZVRA stock presents both potential and risks for long-term investors.
Confirms Receipt of Two Director Nominees from Daniel J. ManglessStockholders Are Not Required to Take Action at This TimeCELEBRATION, Fla., ...
In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on GeoVax Labs (GOVX – Research Report), with a price target ...
Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback